Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Summit Therapeutics Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.85 (market cap $1.45B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 9.5× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and Summit Therapeutics Inc for 16 Days on average.
| QQQE | SMMT | |
|---|---|---|
Market Cap | $1.45B | $13.71B |
Volume | 323,568 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $26.38 |
52-Week Low | $96.06 | $12.43 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.68, down 0.17% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators are neutral. The equal-weight strategy reduces technology concentration compared to the standard NASDAQ-100 ETF, offering diversified exposure to large-cap growth stocks. Recent news highlights tactical preference for QQQE over QQQ due to its fundamental and technical positioning.
The outlook for QQQE is positive, driven by its equal-weight approach mitigating single-stock risk and capturing broad Nasdaq growth. Key risks include market volatility and sector concentration shifts. Investment appeal lies in its structural diversification, though reliance on tech sector performance remains a factor for investors to weigh.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
